Clinical Hold For Merck KGaA’s BTK Inhibitor Evobrutinib For MS Raises Class Safety Fears

Third To Be Hit With MS Clinical Hold

 
• By Ayisha Sharma
Stop sign
The Hold Means New Patients Cannot Be Treated With Evobrutinib • Source: Shutterstock

More from Clinical Trials

More from R&D